BioTech IP Review

Adenovirus‑Based SARS‑CoV‑2 Vaccine

WO 2021243219 A1

Published: Dec 2, 2021 (priority filing May 29, 2020)
Assignee: Janssen (Johnson & Johnson) via its vaccine unit
Title: Adenovirus‑Based SARS‑CoV‑2 Vaccine
Focus: Genetic constructs and compositions of viral vectors (e.g., adenovirus serotype 26) encoding SARS‑CoV‑2 antigen(s) for vaccination against COVID‑19.

What This Patent Covers

This patent application and related filings describe:

  • Non‑replicating adenoviral vectors (such as Ad26) engineered to carry genetic material encoding a coronavirus antigen (e.g., the SARS‑CoV‑2 spike protein) that, when delivered into human cells, triggers a protective immune response against COVID‑19.
  • Compositions of the viral vector vaccine, including how the antigen sequence is arranged and presented within the vector to elicit a robust immune response.
  • Vaccination methods where administering these vaccine compositions stimulates neutralizing antibodies and cellular immunity that prevent infection or severe disease.

The patent family risks broad coverage around how the adenovirus vector and its genetic payload are configured and used for immunization.

Why This Is Important

1. Foundation for a Major Vaccine Product

This patent underpins the technology behind the Janssen Ad26.COV2.S COVID‑19 vaccine — a once‑daily single‑dose vaccine authorized in many regions starting in early 2021. It uses a modified human adenovirus serotype 26 (Ad26) vector to deliver the SARS‑CoV‑2 spike protein gene, inducing immunity.

2. Global Public Health & Commercial Impact

Although Ad26.COV2.S was distributed at cost in many settings during the pandemic, it was used worldwide as one of the major COVID‑19 vaccines, especially valued for its single‑dose regimen and simpler cold‑chain requirements compared with some mRNA vaccines.

3. Strategic Technology Platform

The adenoviral vector (Ad26) platform isn’t limited to COVID‑19 — it has applications in vaccines for other infectious diseases and potentially in cancer immunotherapies and other prophylactic vaccines, giving J&J a broader technology base protected by patent claims.

4. Integral to J&J’s IP Estate

Securing patent protection on the viral vector design, constructs, and vaccination methods helps J&J protect its investment and defend against competitive claims — especially important in a crowded vaccine IP landscape with ongoing disputes.

Summary

  • Patent: WO 2021243219 A1 (adenovirus‑based SARS‑CoV‑2 vaccine application, priority May 29, 2020)
  • Assignee: Janssen Pharmaceutical Companies (Johnson & Johnson)
  • Focus: Viral vector vaccine technology using adenovirus (Ad26) encoding spike antigen for protection against COVID‑19
  • Importance: Core intellectual property for the Ad26.COV2.S COVID‑19 vaccine / Jcovden, supporting major global public health deployment and reinforcing J&J’s vaccine technology platform in a highly strategic bioscience area.

Leave a comment